Stockreport

Neurogene Announces Recent Achievements and Anticipated 2026 Key Milestones for NGN-401, a Potential Best-in-Class Gene Therapy for Rett Syndrome

Neurogene Inc.  (NGNE) 
PDF Dosed multiple participants in Embolden™ registrational trial in fourth quarter of 2025Completion of dosing in Embolden expected in second quarter of 2026Plan to present [Read more]